Journals / Retina-Vitreus / 2008 / Cilt: 16 - Sayı: 1

Our treatment results of retinal capillary hemangioma

Retina kapiller hemanjiyomunda tedavi sonuçlarımız

Pages
55–61
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Regression can be achieved with effective treatment methods.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:To determine the treatment modalities and results in patients who were followed up with a diagnosis of retinal capillary hemangioma.
📊
Key Findings & Data:Materials and Methods: The records of 5 patients (1 female, 4 male), aged 13-44 years, with a diagnosis of retinal capillary hemangioma, were retrospectively reviewed, and treatment alternatives and results were discussed.
💡
Conclusion & Impact:Regression can be achieved with effective treatment methods.
🔬Design:Review & Systematic Survey
📍Scope:Comprehensive Sample
⚙️Variables:Vitreus içi enjeksiyon · Hemanjiyom · Işık koagülasyonu

Abstract

To determine the treatment modalities and results in patients who were followed up with a diagnosis of retinal capillary hemangioma. Materials and Methods: The records of 5 patients (1 female, 4 male), aged 13-44 years, with a diagnosis of retinal capillary hemangioma, were retrospectively reviewed, and treatment alternatives and results were discussed. Results: Laser photocoagulation, photodynamic therapy, and intravitreal bevacuzimab (Avastin) were applied in combination or individually. During a mean follow-up of 6-22 months, 4 of the 5 patients showed an improvement with treatment, and an increase in visual acuity was observed. Advanced visual loss developed in 1 patient, who was admitted during the late stage and discontinued follow-up. Conclusion: Retinal capillary hemangioma is a vasoproliferative tumor that may cause vision loss. Regression can be achieved with effective treatment methods.

Özet

Bu çalışmada retina kapiller hemanjiyomu tanısıyla ta- kip ettiğimiz hastaların tedavi seçeneklerini ve sonuçlarını değerlendirmek amaçlanmıştır Gereç ve Yöntem: Yaşları 13-44 yıl arası değişen retinal ka- piller hemanjiyom tanısı almış, 5 hastanın (1’i kadın 4’ü erkek) verileri retrospektif olarak incelenerek, tedavi seçe- nekleri ve sonuçları tartışıldı. Bulgular: Olgulara lazer fotokoagülasyon, fotodinamik teda- vi, intravitreal bevacuzimab (Avastin) tedavilerinden biri veya kombinasyonları uygulandı. Olguların ortalama 6-22 ay takiplerinde; 5 olgunun 4’ünde tedaviye olumlu cevap alınıp, lezyonlarda gerileme ve görme keskinliğinde artış tespit edildi. Geç dönemde başvuran ve takibine devam etmeyen 1 hastada ileri görme kaybı gelişti. Sonuç: Retinal kapiller hemanjiyom görme kaybı ile sonuçla- nabilen vazoproliferatif bir tümördür. Bununla birlikte etkin tedavi yöntemleri uygulandığında regresyon sağlanabil- mektedir.

🔖

Cite This Article

SOYLU, M., ÖZCAN, A. A., DÜLGER, E., ÇAYLI, S. (2008). Our treatment results of retinal capillary hemangioma. Retina-Vitreus, Cilt: 16 - Sayı: 1, 55–61. https://ajindex.com/articles/308109

References (15)

  1. Singh AD, Nouri M, Shields CL: Treatment of retinal capillary he- mangioma. Ophthalmology. 2002;109:1799-1806
  2. Buelow M, Pape S, Hoerauf H: Systemic bevacizumab treatment of a juxtacapillary retinal hemangioma. Acta Ophthalmol. 2007: 85:114-116
  3. Manzano RPA, Peyman GA, Khan P et al.: Testing intravitreal to-, xicity of bevacizumab (Avastin). Retina. 2006;26:257-261
  4. Schmidt-Erfurth UM, Kuserow C, Barbazetto IA, et al.: Benefits and complications of photodynamic therapy of papillary capillary hemangiomas. Ophthalmology. 2002;159:1256-1266
  5. Sobacı G. Retinanın Diğer Anevrizmal Hastalıkları. Ret-Vit. 2004; 12:158-160
  6. Atebara NH: Retinal capillary hemangioma treated with vertopor- firin photodynamic therapy. Am J Ophthalmol. 2002;134:788- 790
  7. Aaberg TM: Three cases of large retinal capillary hemangiomas treated with vertoporfin and photodynamic therapy. Arch Oph- thalmol. 2005:123:328-333
  8. Aiello LP George DJ, Cahill MT, et al. Rapid and durable recovery, of visual function in a patient with von Hippel-Lindau syndrome after systemic therapy with vascular endothelial growth factor in- hibitor SU 5416. Ophthalmology 2002;109:1745-1751
  9. Madhusudan S, Deplanque G, Braybrooke JP et al.: Antiangiioge-, nic therapy for von Hippel-Lindau disease. JAMA. 2004;291:943- 944
  10. Girmens JF, Erginay A, Massin P et al.: Treatment of von Hippel-, Lindau retinal hemangioblastoma by the vascular endothelial growth factor inhibitor SU 5416 is more effective for associated macular edema than for hemangioblastomas. Am J Ophthalmol. 2003;136:194-196
  11. Goff MJ, Johnson RN, McDonald HR, et al.: Intravitreal bevaci- zumab for previously treated choroidal neovascularization from age-related macular degeneration. Retina. 2007;27:432-438
  12. Avery RL, Pieramici DJ, Rabena MD, et al.: Intravitreal bevacizu- mab (Avastin) for neovascular age-related macular degenerati- on. Ophthalmology. 2006;113:363-372
  13. Michels S, Rosenfeld PJ, Puliafito CA, et al.: Systemic bevacizu- mab (Avastin) therapy for neovascular age-related macular de- generation: twelve week results of an uncontrolled open-label clinical study. Ophthalmology. 2005;112:1035-1047
  14. Dahr SS, Cusick M, Rodriguez-Coleman H, et al.: Intravitreal anti-vascular endothelial growth factor therapy with pegaptanib for advanced von Hippel-Lindau disease of the retina. Retina. 2007;27:150-158
  15. Uysal Y, Erdurman C, Sobacı G, ve ark.: Retinal kapiller hemanji- yomun hiperisin ile güçlendirilmiş